POAI
Predictive Oncology Inc.
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$4.91
+6.28%Price chart
Apr 17Apr 22Apr 27Apr 30May 5May 8May 13May 18
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.0x
Market Cap
$3.55M
MomentumView details →
1D Return
+6.28%
YTD Return
−34.55%
RSI (14)
45.2
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.0x
Market Cap
$3.55M
RSI (14)
45.2
MomentumView details →
1D Return
+6.28%
YTD Return
−34.55%
SummaryUpdated Mar 1, 2026
Predictive Oncology Inc. (NASDAQ:POAI) is a knowledge-driven biotechnology company founded in 2002 and headquartered in Eagan, Minnesota. Originally incorporated as Precision Therapeutics Inc., the company rebranded to its current name in June 2019 to better reflect its focus on artificial intelligence-driven cancer research. The company has evolved from a traditional medical device manufacturer into a science-driven organization that leverages artificial intelligence and machine learning to advance personalized cancer therapies and drug discovery processes.
Similar companies
Latest newsMore news →
Axe Compute and Duos Technologies announced agreements to add up to 55 MW of AI data center capacity across multiple U.S. locations.18d agoAxe Compute Inc. reported financial results for the second quarter ended June 30, 2026, with revenue growing more than 90x sequentially from Q1 2026 and more than $2.8 billion in new contracts signed during the quarter, bringing 2026 signed contracted value to over $3 billion.21d agoAxe Compute secures a $1.5 billion five-year dedicated AI infrastructure contract with $534 million prepayments, lifting its 2026 signed contracted value above $3 billion.39d ago